NCT03014089View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 21, 2016

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Zika Virus
Interventions
BIOLOGICAL

mRNA-1325

Escalating dose levels

OTHER

Placebo

Trial Locations (3)

32934

Melbourne

61614

Peoria

92108

San Diego

All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

ModernaTX, Inc.

INDUSTRY

NCT03014089 - Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter